The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

HIV activist Solly Nduku was recently elected to the top civil society position at the South African National Aids Council.

People with HIV are more likely to have severe premenstrual syndrome (PMS) symptoms than others, such as: In the United States, about 2% of transgender people make up new HIV diagnoses.